TY - JOUR
T1 - Finding a balance in the vaginal microbiome
T2 - How do we treat and prevent the occurrence of bacterial vaginosis?
AU - Joseph, Rebecca Jane
AU - Ser, Hooi Leng
AU - Kuai, Yi He
AU - Tan, Loh Teng Hern
AU - Arasoo, Valliammai Jayanthi Thirunavuk
AU - Letchumanan, Vengadesh
AU - Wang, Lijing
AU - Pusparajah, Priyia
AU - Goh, Bey Hing
AU - Ab Mutalib, Nurul Syakima
AU - Chan, Kok Gan
AU - Lee, Learn Han
N1 - Funding Information:
This work was supported by Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS) Strategic Grant 2021 (Grant Code: SED-000068), Fundamental Research Grant Scheme (FRGS/1/2019/SKK08/MUSM/02/7), External Industry Grant from Biomerge Sdn Bhd to LHL (Vote no. BMRG2018-01), and University of Malaya Research Grant (FRGS grant to KGC grant no: FP022-2018A).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6/15
Y1 - 2021/6/15
N2 - Bacterial vaginosis (BV) has been reported in one-third of women worldwide at different life stages, due to the complex balance in the ecology of the vaginal microbiota. It is a common cause of abnormal vaginal discharge and is associated with other health issues. Since the first description of anaerobic microbes associated with BV like Gardnerella vaginalis in the 1950s, researchers have stepped up the game by incorporating advanced molecular tools to monitor and evaluate the extent of dysbiosis within the vaginal microbiome, particularly on how specific microbial population changes compared to a healthy state. Moreover, treatment failure and BV recurrence rate remain high despite the standard antibiotic treatment. Consequently, researchers have been probing into alternative or adjunct treatments, including probiotics or even vaginal microbiota transplants, to ensure successful treatment outcomes and reduce the colonization by pathogenic microbes of the female reproductive tract. The current review summarizes the latest findings in probiotics use for BV and explores the potential of vaginal microbiota transplants in restoring vaginal health.
AB - Bacterial vaginosis (BV) has been reported in one-third of women worldwide at different life stages, due to the complex balance in the ecology of the vaginal microbiota. It is a common cause of abnormal vaginal discharge and is associated with other health issues. Since the first description of anaerobic microbes associated with BV like Gardnerella vaginalis in the 1950s, researchers have stepped up the game by incorporating advanced molecular tools to monitor and evaluate the extent of dysbiosis within the vaginal microbiome, particularly on how specific microbial population changes compared to a healthy state. Moreover, treatment failure and BV recurrence rate remain high despite the standard antibiotic treatment. Consequently, researchers have been probing into alternative or adjunct treatments, including probiotics or even vaginal microbiota transplants, to ensure successful treatment outcomes and reduce the colonization by pathogenic microbes of the female reproductive tract. The current review summarizes the latest findings in probiotics use for BV and explores the potential of vaginal microbiota transplants in restoring vaginal health.
KW - Bacterial vaginosis
KW - Gardnerella
KW - Lactobacillus
KW - Microbiome
KW - Probiotics
KW - VMT
UR - http://www.scopus.com/inward/record.url?scp=85108785970&partnerID=8YFLogxK
U2 - 10.3390/antibiotics10060719
DO - 10.3390/antibiotics10060719
M3 - Review Article
C2 - 34203908
AN - SCOPUS:85108785970
SN - 2079-6382
VL - 10
JO - Antibiotics
JF - Antibiotics
IS - 6
M1 - 719
ER -